hero image

Biogen to Participate in the Cowen 43rd Annual Health Care Conference

February 20, 2023 News Release

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in the Cowen 43rd Annual Health Care Conference. The webcast will be live on Monday, March 6, 2023, at 9:50 a.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at investors.biogen.com.  An archived version of the webcast will be available following the presentation.

About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

 

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

thumb
February 13, 2024
Biogen Reports Fourth Quarter and Full Year 2023 Results
thumb
February 12, 2024
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients